Ascentage Pharma Group International (AAPG) Receivables - Net (2023 - 2025)
Ascentage Pharma Group International (AAPG) has disclosed Receivables - Net for 3 consecutive years, with $35.7 million as the latest value for Q4 2025.
- For Q4 2025, Receivables - Net rose 208.1% year-over-year to $35.7 million; the TTM value through Dec 2025 reached $35.7 million, up 208.1%, while the annual FY2025 figure was $36.2 million, 217.56% up from the prior year.
- Receivables - Net hit $35.7 million in Q4 2025 for Ascentage Pharma Group International, up from $11.6 million in the prior quarter.
- Across five years, Receivables - Net topped out at $35.7 million in Q4 2025 and bottomed at $11.6 million in Q4 2024.
- Average Receivables - Net over 3 years is $22.5 million, with a median of $20.3 million recorded in 2023.
- Year-over-year, Receivables - Net crashed 42.88% in 2024 and then soared 208.1% in 2025.
- Ascentage Pharma Group International's Receivables - Net stood at $20.3 million in 2023, then crashed by 42.88% to $11.6 million in 2024, then skyrocketed by 208.1% to $35.7 million in 2025.
- According to Business Quant data, Receivables - Net over the past three periods came in at $35.7 million, $11.6 million, and $20.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.